English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Acellular dermal matrices can successfully heal wounds. This study's goal was to compare clinical outcomes of a novel, open‐structure human reticular acellular dermis matrix ( HR‐ADM ) to facilitate wound closure in non‐healing diabetic foot ulcers ( DFUs ) versus  DFUs  treated with standard of care ( SOC ). Following a 2‐week screening period in which  DFUs  were treated with offloading and moist wound care, patients were randomised to either  SOC  alone or  HR‐ADM  plus  SOC  applied weekly for up to 12 weeks. At 6 weeks, the primary outcome time, 65% of the  HR‐ADM ‐treated  DFUs  healed (13/20) compared with 5% (1/20) of  DFUs  that received  SOC  alone. At 12 weeks, the proportions of  DFUs  healed were 80% and 20%, respectively. Mean time to heal within 12 weeks was 40 days for the  HR‐ADM  group compared with 77 days for the  SOC  group. There was no incidence of increased adverse or serious adverse events between groups or any adverse events related to the graft. Mean and median graft costs to closure per healed wound in the  HR‐ADM  group were $1475 and $963, respectively. Weekly application of  HR‐ADM  is an effective intervention for promoting closure of non‐healing  DFUs .

international wound journal

A prospective, randomised, controlled, multicentre clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers